Please login to the form below

Not currently logged in
Email:
Password:

tanezumab

This page shows the latest tanezumab news and features for those working in and with pharma, biotech and healthcare.

Pfizer drops neuroscience R&D, cutting 300 jobs

Pfizer drops neuroscience R&D, cutting 300 jobs

The move is part of a redirection of its research spending - rather than a reduction - and will not affect late-stage projects such as nerve growth factor-1 inhibitor tanezumab for

Latest news

More from news
Approximately 5 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    prostate cancer. 2, 400. Pfizer / Lilly. Co-development. Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics